



## Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2009

January 29, 2009

### Company to Webcast Presentation on February 9

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the BIO CEO & Investor Conference on Monday, February 9, 2009 at 3:15 pm (ET) at the Waldorf Astoria Hotel in New York.

In addition, Safi Bahcall, Ph.D., President and CEO, Synta Pharmaceuticals will be a panelist in the BIO CEO therapeutic workshop **Oncology: The Forecast for the Melanoma Market—Partly Sunny or Mostly Cloudy?** at 12:30 pm (ET) on Tuesday, February 10. Dr. Bahcall will discuss oxidative stress induction as a new therapeutic approach to treating melanoma and other cancers.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, [www.syntapharma.com](http://www.syntapharma.com). The panel will not be webcast.

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

Source: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.

Rob Kloppenburg, 781-541-7125

or

MacDougall Biomedical Communications

Doug MacDougall, 781-235-3060